OncologyPharmaUnited States FDA Clears First PROTAC Drug for Breast Cancer, Validating a New Therapeutic Mechanism Vepdegestrant’s May 1 approval for ESR1-mutant advanced breast cancer marks the first PROTAC-class drug cleared by the FDA, with VERITAC-2 trial data showing a hazard ratio of 0.70 over fulvestrant. By Fernando PafumiMay 24, 20266 Comments
IHME: Global Health Funding Falls Another 5% in 2026 After Hitting Lowest Level Since 2012 Nov 16, 2026
You must be logged in to post a comment.